Option Care Health’s (OPCH) Neutral Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. restated their neutral rating on shares of Option Care Health (NASDAQ:OPCH) in a research note published on Wednesday morning,Benzinga reports. The brokerage currently has a $33.00 price objective on the stock.

Other equities research analysts have also recently issued reports about the stock. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $24.00 price objective (down from $26.00) on shares of Option Care Health in a research note on Thursday, July 30th. UBS Group reiterated a “buy” rating on shares of Option Care Health in a research report on Tuesday, September 22nd. Wall Street Zen raised shares of Option Care Health from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Citizens Jmp downgraded shares of Option Care Health from a “market outperform” rating to a “hold” rating in a research report on Wednesday. Finally, Zacks Research raised shares of Option Care Health from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Two analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $29.17.

Option Care Health Stock Up 0.1%

OPCH opened at $31.07 on Wednesday. Option Care Health has a 12 month low of $18.01 and a 12 month high of $36.80. The company has a debt-to-equity ratio of 0.91, a current ratio of 1.47 and a quick ratio of 0.98. The stock has a market cap of $4.65 billion, a P/E ratio of 23.36, a P/E/G ratio of 1.89 and a beta of 0.58. The stock’s 50 day moving average price is $24.25 and its 200 day moving average price is $23.64.

Option Care Health (NASDAQ:OPCH) last announced its quarterly earnings results on Wednesday, July 29th. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.02. Option Care Health had a return on equity of 18.74% and a net margin of 3.68%. The company had revenue of $1.44 billion during the quarter, compared to analyst estimates of $1.42 billion. During the same quarter in the previous year, the firm posted $0.41 EPS. The firm’s quarterly revenue was up 1.9% on a year-over-year basis. Option Care Health has set its FY 2026 guidance at 1.850-1.920 EPS. As a group, research analysts predict that Option Care Health will post 1.70 earnings per share for the current year.

Institutional Trading of Option Care Health

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Harbor Investment Advisory LLC bought a new position in Option Care Health during the second quarter valued at about $48,000. Nykredit A S acquired a new position in Option Care Health during the second quarter worth about $56,000. Public Employees Retirement System of Ohio bought a new stake in Option Care Health in the second quarter worth about $66,000. KBC Group NV raised its position in Option Care Health by 22.1% in the first quarter. KBC Group NV now owns 5,453 shares of the company’s stock worth $147,000 after acquiring an additional 988 shares in the last quarter. Finally, Summitry LLC bought a new stake in Option Care Health in the first quarter worth about $200,000. Institutional investors own 98.05% of the company’s stock.

Key Option Care Health News

Here are the key news stories impacting Option Care Health this week:

• Positive Sentiment: The proposed CD&R and McKesson buyout provides a clear cash value of $32.05 per share and represents a substantial premium to Option Care Health’s pre-deal trading levels. Option Care Health agrees to $32.05 buyout by CD&R and McKesson
• Positive Sentiment: One analysis argues that Option Care Health may still be undervalued despite the $5.8 billion transaction, supporting the view that the offer could be attractive relative to the company’s underlying business value. Option Care Health stock may be undervalued despite the $5.8 billion buyout
• Neutral Sentiment: JPMorgan reaffirmed a “Neutral” rating, indicating limited expected upside beyond the announced offer price and a focus on deal completion rather than ongoing operating growth. JPMorgan reaffirms neutral rating
• Neutral Sentiment: Analyst price-target coverage remains relevant mainly for gauging the spread to the $32.05 cash consideration, as the pending acquisition limits the importance of standalone valuation targets. Option Care Health analyst price targets
• Negative Sentiment: Several firms have reduced their ratings: Citizens JMP moved to “Hold,” Barrington Research downgraded the stock to “Market Perform,” and Truist cut its rating from “Strong Buy” to “Hold.” The downgrades signal reduced upside after the buyout announcement. Citizens JMP lowers rating to hold Barrington Research downgrade
• Negative Sentiment: Kahn Swick & Foti is investigating whether the $32.05 consideration and sale process were adequate. Such scrutiny could create legal or timing uncertainty, although the investigation does not itself indicate that the transaction will fail. Investor alert regarding the proposed sale

About Option Care Health

Option Care Health, Inc (NASDAQ: OPCH) is a provider of home and alternate-site infusion services in the United States. The company works with patients, physicians, hospitals, health plans and pharmaceutical manufacturers to deliver and manage infusion therapy outside traditional hospital settings, including in patients’ homes, ambulatory infusion suites and other community-based locations.

Its services include the provision and administration of specialty medications and other infusion therapies for conditions such as infections, immune disorders, chronic diseases and nutritional deficiencies.